:

How much does Prolia decrease fracture risk? Understanding the data from clinical trials

According to the landmark FREEDOM clinical trial, Prolia (denosumab) reduced the relative risk of new vertebral fractures by 68% and hip fractures by 40% in postmenopausal women with osteoporosis over three years compared to a placebo. This data is central to understanding how much Prolia decreases fracture risk in high-risk patients.